Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Next Previous
X
Search
Trial Profile

An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
  • Focus Adverse reactions
  • Acronyms TETON-OLE
  • Sponsors United Therapeutics Corporation

    • Most Recent Events

    • 27 Aug 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2026.
    • 22 May 2024 Trial design presented at the 120th International Conference of the American Thoracic Society.
    • 24 Aug 2022 According to a United Therapeutics Corporation media release, additional details of the trial will be presented at the European Respiratory Society International Congress 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top